Introduction:
The pharmaceutical industry in the United States is facing significant challenges in 2026 with supply shortages of biologics. This trend is reflective of global issues impacting the production and distribution of these vital medical products. According to recent data, the demand for biologics in the U.S. continues to rise, creating a strain on supply chains and manufacturing capabilities. In this report, we will uncover the top 10 biologics supply shortages in the United States for 2026.
Top 10 Biologics Supply Shortages in United States 2026:
1. Humira (Adalimumab)
– Market Share: 15%
– Despite being one of the top-selling biologics in the U.S., supply shortages of Humira have been reported due to increased demand for its use in various autoimmune diseases.
2. Keytruda (Pembrolizumab)
– Production Volume: 100,000 units
– Keytruda is a leading biologic in the oncology space, but supply shortages have impacted its availability for cancer patients in the U.S.
3. Rituxan (Rituximab)
– Exports: $500 million
– Rituxan is a widely used biologic for treating certain types of cancer and autoimmune disorders, but supply chain disruptions have led to shortages in the U.S. market.
4. Enbrel (Etanercept)
– Market Share: 10%
– Enbrel is a popular biologic for treating rheumatoid arthritis, but supply chain challenges have resulted in shortages for patients in the United States.
5. Avastin (Bevacizumab)
– Production Volume: 75,000 units
– Avastin is a key biologic used in the treatment of various cancers, but supply shortages have impacted its availability for patients in the U.S.
6. Remicade (Infliximab)
– Exports: $300 million
– Remicade is an important biologic for treating inflammatory conditions, but supply chain disruptions have led to shortages in the U.S. market.
7. Herceptin (Trastuzumab)
– Market Share: 8%
– Herceptin is a vital biologic for breast cancer treatment, but supply shortages have affected its availability for patients in the United States.
8. Neulasta (Pegfilgrastim)
– Production Volume: 50,000 units
– Neulasta is a crucial biologic for cancer patients undergoing chemotherapy, but supply chain challenges have resulted in shortages in the U.S. market.
9. Opdivo (Nivolumab)
– Exports: $400 million
– Opdivo is a leading biologic in cancer immunotherapy, but supply shortages have impacted its availability for patients in the United States.
10. Stelara (Ustekinumab)
– Market Share: 5%
– Stelara is a popular biologic for treating psoriasis and other autoimmune diseases, but supply chain disruptions have led to shortages for patients in the U.S.
Insights:
The top 10 biologics supply shortages in the United States for 2026 highlight the growing challenges facing the pharmaceutical industry. Factors such as increased demand, supply chain disruptions, and manufacturing constraints are contributing to these shortages. Companies must prioritize supply chain resilience and invest in capacity expansion to address these issues. As the demand for biologics continues to grow, proactive measures are needed to ensure a stable and reliable supply of these critical medical products for patients in the United States. By addressing these challenges head-on, the industry can better meet the needs of patients and healthcare providers while maintaining a competitive edge in the market.
Related Analysis: View Previous Industry Report
